Gilder Gagnon Howe & CO LLC Aurinia Pharmaceuticals Inc. Transaction History

Gilder Gagnon Howe & CO LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $5,834 - $10,853	-876 Reduced 0.49%	179,090 $1.35 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $160,822 - $230,003	-17,969 Reduced 9.08%	179,966 $1.81 Million
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $26,652 - $59,616	2,652 Added 1.36%	197,935 $2.45 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $70,568 - $131,294	3,969 Added 2.07%	195,283 $4.47 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $8,186 - $17,638	749 Added 0.39%	191,314 $4.23 Million
Q2 2021 Aug 16, 2021	BUY	$10.0 - $14.52 $57,400 - $83,344	5,740 Added 3.11%	190,565 $2.47 Million
Q1 2021 May 17, 2021	BUY	$12.3 - $18.73 $56,272 - $85,689	4,575 Added 2.54%	184,825 $2.4 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $2.33 Million - $2.89 Million	180,250 New	180,250 $2.49 Million

227

58.9M

949K

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.17B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.